BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 18375360)

  • 1. Translational research in breast cancer.
    Chu QD; Holm N; Byrnes K; Li BD
    Surg Oncol Clin N Am; 2008 Apr; 17(2):421-38, x. PubMed ID: 18375360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microarray-based gene expression profiling as a clinical tool for breast cancer management: are we there yet?
    Correa Geyer F; Reis-Filho JS
    Int J Surg Pathol; 2009 Aug; 17(4):285-302. PubMed ID: 19103611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of genomic tools for the molecular understanding of breast cancer and to guide personalized medicine.
    Foekens JA; Wang Y; Martens JW; Berns EM; Klijn JG
    Drug Discov Today; 2008 Jun; 13(11-12):481-7. PubMed ID: 18549973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NCI launches an innovative design for a breast cancer clinical trial.
    Whitworth A
    J Natl Cancer Inst; 2006 Sep; 98(17):1178-9. PubMed ID: 16954467
    [No Abstract]   [Full Text] [Related]  

  • 5. Gene expression-based diagnosis of efficacy of chemotherapy for breast cancer.
    Miki Y
    Breast Cancer; 2010 Apr; 17(2):97-102. PubMed ID: 20013078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular profile of the BCL2 family of the apoptosis related genes in breast cancer cells after treatment with cytotoxic/cytostatic drugs.
    Thomadaki H; Scorilas A
    Connect Tissue Res; 2008; 49(3):261-4. PubMed ID: 18661356
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Proteomics and breast cancer: new perspectives and limitations].
    Hondermarck H
    Pathol Biol (Paris); 2006 May; 54(4):194-8. PubMed ID: 16632259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preoperative chemotherapy is safe in early breast cancer, even after 10 years of follow-up; clinical and translational results from the EORTC trial 10902.
    van Nes JG; Putter H; Julien JP; Tubiana-Hulin M; van de Vijver M; Bogaerts J; de Vos M; van de Velde CJ;
    Breast Cancer Res Treat; 2009 May; 115(1):101-13. PubMed ID: 18484198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacology, pharmacogenetics, and pharmacoepidemiology: three ps of individualized therapy.
    Dawood S
    Cancer Invest; 2009 Oct; 27(8):809-15. PubMed ID: 19731103
    [No Abstract]   [Full Text] [Related]  

  • 10. Basal and triple-negative breast cancers: impact on clinical decision-making and novel therapeutic options.
    Voduc D; Nielsen TO
    Clin Breast Cancer; 2008 Dec; 8 Suppl 4():S171-8. PubMed ID: 19158038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacogenetics of breast cancer: toward the individualization of therapy.
    Chang JC; Hilsenbeck SG; Fuqua SA
    Cancer Invest; 2009 Aug; 27(7):699-703. PubMed ID: 19637041
    [No Abstract]   [Full Text] [Related]  

  • 12. Molecular analysis of hormone receptor positive (luminal) breast cancers: what have we learnt?
    Loi S
    Eur J Cancer; 2008 Dec; 44(18):2813-8. PubMed ID: 18990560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MicroRNA expression and its implications for the diagnosis and therapeutic strategies of breast cancer.
    Shi M; Guo N
    Cancer Treat Rev; 2009 Jun; 35(4):328-34. PubMed ID: 19171434
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Breast cancer special types: why bother?
    Reis-Filho JS; Lakhani SR
    J Pathol; 2008 Dec; 216(4):394-8. PubMed ID: 18798222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Chemotherapy for breast cancer].
    Nakayama T; Noguchi S
    Gan To Kagaku Ryoho; 2011 Dec; 38(13):2569-73. PubMed ID: 22319837
    [No Abstract]   [Full Text] [Related]  

  • 16. Mammosphere-derived gene set predicts outcome in patients with ER-positive breast cancer.
    Kok M; Koornstra RH; Margarido TC; Fles R; Armstrong NJ; Linn SC; Van't Veer LJ; Weigelt B
    J Pathol; 2009 Jul; 218(3):316-26. PubMed ID: 19353633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II genomics study of ixabepilone as neoadjuvant treatment for breast cancer.
    Baselga J; Zambetti M; Llombart-Cussac A; Manikhas G; Kubista E; Steger GG; Makhson A; Tjulandin S; Ludwig H; Verrill M; Ciruelos E; Egyhazi S; Xu LA; Zerba KE; Lee H; Clark E; Galbraith S
    J Clin Oncol; 2009 Feb; 27(4):526-34. PubMed ID: 19075286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MicroRNA involvement in the pathogenesis and management of breast cancer.
    Khoshnaw SM; Green AR; Powe DG; Ellis IO
    J Clin Pathol; 2009 May; 62(5):422-8. PubMed ID: 19398594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetics and genome-wide association studies: surgery-guided algorithm and promise for future breast cancer personalized surgery.
    Roukos DH
    Expert Rev Mol Diagn; 2008 Sep; 8(5):587-97. PubMed ID: 18785807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lower level of MAPK expression is associated with anthracycline resistance and decreased survival in patients with hormone receptor negative breast cancer.
    Derin D; Eralp Y; Ozluk Y; Yavuz E; Guney N; Saip P; Igci A; Ozmen V; Kücücük S; Aslay I; Aydiner A; Topuz E
    Cancer Invest; 2008 Aug; 26(7):671-9. PubMed ID: 18608215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.